EARO

Experimental Drug Development Centre
Academic Research Organisation

EARO REVIEW

2020 - 2022

AN INITIATIVE OF EDDC Experimental Drug Development Centre



CONTENTS

WELCOME

The EDDC Academic Research Organisation (EARO) was launched by the Experimental Drug Development Centre (EDDC)'s leadership in mid 2020, with the primary objective of facilitating the community's access to EDDC's capabilities and technologies.

In our maiden year, we obtained invaluable feedback from our colleagues in academia, biotech and multi-national companies on how EARO could best address local capability gaps to enable the progress of drug discovery projects. With this, we began to offer three different service models from 2021:

- **ACCESS** where EARO provides client's staff with training and direct access to our equipment
- **ASSIST** where EARO provides regular consultation and shares the project execution, in addition to Access
- **COMPREHENSIVE** where EARO manages and performs projects from start to end

The three modes allowed us to provide a wide variety of services and to cater to different needs and budget requirements.

As a result, in 2021, we partnered with 34 unique research groups from all sectors of the ecosystem (Academia, Biotech, Start-up and MNC). We had added high-throughput phenomics (HTP) to our service offering, and this was met by strong demand from the community. Therefore, 2022 saw a sharp increase in the number of services delivered and a high client retention. We also started to work with an MNC on multiple projects. Through the relationship built, we also embarked on the development of a technology platform and organized a joint symposium with this company.

We are proud that EARO has become an enabler for the vibrant research community in Singapore. By engaging with our partners through the years, we have gained a greater understanding of the community's needs. We are now working towards extending our scope to address these needs.

EARO is now celebrating its third year of operation. Hence, we wanted to reflect on our achievements and share our thoughts on the future of this initiative through this report.

CHRISTOPHE BODENREIDER
Executive Director, EARO

OUR MISSION AND PHILOSOPHY

EARO aims to **drive the innovation and advancement of translational drug discovery** in Singapore, and to enable our scientific community to do so **cost effectively**, by providing **access to EDDC's specialised technologies, expertise, and connections**.

ENHANCE ACCESS TO EDDC CAPABILITIES

FOSTER DEEP RELATIONS WITH THE ECOSYSTEM



ACCELERATE DRUG DISCOVERY RESEARCH

EARO'S JOURNEY AND SUPPORT TO THE COMMUNITY

EARO was launched in mid 2020, with the goal of facilitating the local community's access to technologies available at EDDC.

2021 marked the start of our three service models (ACCESS, ASSIST, COMPREHENSIVE). We added high-content imaging to our suite of capabilities. EARO's website was launched.

In 2022, EARO was granted ISO9001:2015 certification, highlighting our high-quality standards. The number of COMPREHENSIVE services increased sharply.

2020

45 SERVICES COMPLETED

19 RESEARCH GROUPS SERVED

13 EXTERNAL USERS ACCESSING EARO TECHNOLOGIES

2021

115 SERVICES COMPLETED

34 RESEARCH GROUPS SERVED

59 EXTERNAL USERS ACCESSING EARO TECHNOLOGIES

2022

155 SERVICES COMPLETED

30 RESEARCH GROUPS SERVED

61 EXTERNAL USERS ACCESSING EARO TECHNOLOGIES

SOLUTIONS FOR OPTIMAL OUTCOMES

ACCESS TO CAPABILITIES MADE EASY

To ensure that every research group in the community can make optimal use of EDDC's capabilities, we created three unique service models to address the specific needs and interests of our clients. These models range from basic technology access and project assistance to more comprehensive, tailored solutions. This allows us to fulfil our mission in an impactful way.



COMPREHENSIVE

An **end-to-end** service model for projects of all sizes - from assay development and piloting to complete execution under a rigorous ISO9001 quality system.

ASSIST

A model where EARO provides our clients **assistance with specific parts of the projects**, with the client staff's executing other parts of the workflow.

ACCESS

Visiting researchers receive necessary training for **direct access to, and independent operation,** of industry-leading high-throughput technologies on a pay-per-use basis.

ISO9001:2015

EARO HAS A ROBUST QUALITY MANAGEMENT SYSTEM

DEDICATION TO EXCELLENCE

One of the achievements we are very proud of is the ISO9001 certification we received in 2022. This recognized the robust quality management system we have put in place. During the surveillance audit in 2023, we received high praise for having zero non-conformities and for the further process improvements we had made.

This certification highlights our commitment to providing the highest quality services to the research community and acknowledges that EARO is operating at international standards.

100%

QUALITY OBJECTIVES MET


SUPPORTING
THE
ECOSYSTEM

SUPPORTING ALL SECTORS OF OUR ECOSYSTEM

EARO has supported the research needs of groups or organisations from all sectors of the ecosystem - universities, hospitals, research institutes, as well as biotech, pharma and consumer health companies. This has allowed us to build strong relationships with the scientific ecosystem, leading to repeat engagements. We have supported most biomedical domains in life sciences R&D - from oncology, fibrosis, metabolic diseases, precision medicine, and rare diseases to small molecule therapies, antibodies, cell therapies, organ-on-chip technologies and digital health solutions.



SUPPORTING TRANSLATIONAL RESEARCH SCIENTISTS

ADVANCING ACADEMIC ENDEAVORS

Resources Deployed
Compound Libraries
Automation Technologies
Drug Discovery Expertise

Defined Outcomes
Validated Hitlist
Chemical Structures
IC50 Values

Benefits
Starting point for a drug discovery program

A/Prof Yu Haojie's team at the National University of Singapore had discovered that an orphan GPCR was a causative factor in some cardiometabolic disease indications. A/Prof Yu wanted to further this discovery by identifying small molecules that modulate the target.

The HTS team at EARO has years of experience in the development of screening strategies for challenging targets. The HTS group worked hand-in-hand with A/Prof Yu's team to design the screening strategy (assay automation, choice of compound libraries) and a screening campaign is underway at the time of this publication.

The screen could lead to the identification of novel inhibitors for this target. With this in hand, A/Prof Yu's team will have a valuable tool compound for pharmacological validation. This will increase the chances for the team to attract private or public funding for the initiation of a drug discovery program.

"I have had the pleasure of engaging with EARO to apply their state-of-art platforms and expertise in a small molecule high-throughput screening campaign. Their resources will enable us to identify novel therapeutic molecules for cardiometabolic disease indications. We are hopeful that we can develop lead compounds targeting disease-causal orphan GPCRs in the near future. The services offered by EARO are invaluable and I would recommend them to anyone looking to advance their R&D objectives."

Sep 2021 - Oct 2022

YU HAOJIE
Assistant Professor
NUS National University of Singapore | Yong Loo Lin School of Medicine

INNOVATIVE BIOIMAGING ANALYSIS THROUGH DEEP LEARNING

SUPPORTING THE BIOTECH ECOSYSTEM

Resources Deployed
High Content Imaging Tech
Image Analysis Expertise

Defined Outcomes
Novel Assay for Cellular Response

Benefits
New Assay Saves Time & Cost

Engine Biosciences is a local biotech company that develops precision medicine therapeutics for oncology and other complex diseases.

Dr Sai Srinivas approached EARO for access to high-content imaging technologies to develop an alternative analysis method to validate their primary biochemical assay results.

EARO began by training Engine Biosciences' staff to use our imaging technology. This then expanded into a close working relationship with Dr Srinivas to create a multiparametric image analysis algorithm. This algorithm can determine nuclear phenotype at the single cell level using just two biomarkers, allowing the detection of cell cycle stages faster than ever before.

The new morphometric method validated the results obtained with the biochemical assay. Moreover, the method makes it possible to quickly predict potential toxicities and mechanisms of action for any new assets in development.

"My initial interaction with EARO was to use the High Content Imaging instruments to develop a new assay. The help I received from them to develop multiplex image analysis pipelines was invaluable. I had a great experience, and we are very satisfied with the services."

U. SAI SRINIVAS
Scientist II
engine Biosciences

Jan - Jun 2022

SUPPORTING FLEDGLING STARTUPS

Resources Deployed
Imaging Technologies
Technology Expertise

Client Expectations
Technology Training
Technology Access

Benefits
Infrastructure to Evaluate Complex Models

Nuevocor is a pre-clinical stage biotech company that develops gene therapy-based medicines for genetic cardiomyopathies using mechanobiology approaches. EARO supported Nuevocor by providing their staff access to our large, high-end equipment, thus saving the company the high capital costs required to purchase and maintain such equipment in-house.

EARO had provided training to several scientists from Nuevocor for high-content imaging. They are now using our equipment on a regular basis to evaluate various 2D and 3D models. They have also started using other technologies available at EARO.

The steady growth in the types of models being evaluated and the frequency of access to EARO technologies by Nuevocor shows that the company recognizes the convenience and value EARO brings. Companies like Nuevocor also challenge us to further develop and improve our existing capabilities.

> “I'd like to give a shoutout to the EARO-HTP team for their tremendous help in training us and granting us access to the capabilities at EDDC. Thanks to the high-end instruments available there, we've been able to accelerate our workflow and enhance the efficiency of our target discovery process. Their assistance has been invaluable, and we're grateful for their support.”

Sep 2022 - Present

JIAMIN LOO
Senior Director, Discovery
Nuevocor

PARTNERING IN DRUG DISCOVERY

DEEPENING RELATIONSHIPS WITH MNCS

In 2021, Ferring Pharmaceuticals engaged EARO for a pilot screening project. This initial collaboration developed into a multi-project partnership involving all EARO platforms. While working on these projects we developed a positive working relationship with the company, that culminated with the initiation of a joint technology development project and the co-organization of a drug discovery symposium in Singapore.

2021

Fragment screening using high-throughput X-ray crystallography

Aug 2021 - Nov 2022



2022

Completed an extensive cell painting screening campaign

Jan - Nov 2022



2022

Co-development of a novel transcriptomics platform

May 2022 - Apr 2023



2022

Joint Ferring-EDDC Symposium on Drug Discovery

Oct 2022

> “Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people build healthy families and live better lives through leadership in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. We use X-ray crystallography and cryo-electron microscopy to understand the mechanism of action and underlying biology of our drug targets, as well as drive rational drug development of antibodies or small molecules. Our footprint is small, and we scale resources to meet our needs through external partnerships with organizations such as EARO. We chose to partner with EARO because of its excellent crystallography technology platform, especially its access to two microfocus beamlines – excellent for small crystals. The two projects we collaborated on were professionally and satisfactorily executed and provided valuable data to jump start drug discovery efforts on a therapeutically important target.”

Aug 2021 - Nov 2022

JEREMIAH JOSEPH
Project Leader

FERRING PHARMACEUTICALS

PARTNERING IN CONSUMER HEALTH SOLUTIONS

BROADENING ALLIANCES WITH MNCS

Resources Deployed
Assay Development
Imaging Technologies
Phenomics Expertise

Stella Wang from P&G's Innovation Centre was interested in evaluating the effect of a natural substance on a certain protein in skin cells. She sought the help of EARO in this endeavour. We deployed our expertise in high content imaging to validate her hypothesis.

Expected Outcomes
Protein Expression Profile
Validation Reports

The HTP team not only determined the protein's cellular abundance and distribution in response to the natural substance; they also discovered that it promotes the development of a morphological phenotype that resembles the protective layers of real epidermis.

Benefits
Novel Evaluation Method

Stella Wang's team was delighted that EARO had brought new insights which were greater than what they had expected from this study. The results were published on EARO's website.

"In partnership with EARO, we successfully explored a new territory of scientific research for our skincare technology.

Leveraging EARO's strong scientific capabilities, we validated our internal hypothesis for the potential of an active skin care ingredient (Glycoxyl™). EARO experts utilized their expertise with advanced technology to develop a comprehensive test protocol in collaboration with us. The original idea was to address the impact of the ingredient on protein levels. During the exploration of the ingredient's properties, EARO experts offered professional recommendations to enable us to fully capture the intricacies of the complex biological phenomenon that occurs during cornification. They continuously improved the test throughout the journey. In the end, the results greatly enlightened us by verifying our hypothesis and led the discovery of new insights.

This break-through result inspired new perspectives for future skin care product development and science communication."

Mar - Jun 2022

STELLA WANG
Scientist
P&G
SINGAPORE
INNOVATION CENTER
#TheFutureMakers

WHAT OUR CLIENTS ARE SAYING

ADVANCING TRANSLATIONAL RESEARCH

Clients who have benefitted from EARO's screening services

High Throughput Screening (COMPREHENSIVE)

Dr Azhar at Cancer Science Institute had derived cell lines from clinical samples in order to discover new line therapies for treatment-resistant lung carcinomas. He turned to EARO to find hit compounds against the disease phenotype. Hopefully, the screen results will help the team to move the project further.

"We have engaged EARO team for their comprehensive service in delivering a cell-based small molecules differential therapeutic-sensitive screening project. Their team was incredibly efficient and professional . They swiftly set up the pilot screen and standardized all the statistical parameters. Moreover, they completed the entire screening process within the stipulated timeframe and provided us with all the necessary information. We look forward to engaging and continuing our partnership with HTP in the future!"

AZHAR BIN ALI

Senior Research Scientist

NUS National University of Singapore | CSI SINGAPORE CANCER SCIENCE INSTITUTE OF SINGAPORE

Sep 2022 – Feb 2023

High Throughput Screening (ASSIST)

Dr Amos Loh at KK Women's and Children's Hospital and Prof Chen Zhi Xiong at National University of Singapore engaged EARO for a screening campaign to find hits against a protein prevalent in specific cancers. EARO assisted by offering guidance on assay optimisation, access to technologies, and data analysis.

"I'm very pleased with the professional service provided by EARO scientists. We have worked with them for the optimization of novel target-based screening campaign using small molecule libraries. They provided excellent scientific support in areas of assay biology and assay miniaturisation. We would definitely engage EARO-HTP team for a larger screening campaign next time!"

AMOS LOH HONG PHENG

Sr. Consultant, Dept. of Pediatric Surgery

KK Women's and Children's Hospital SingHealth

Aug 2022 - Present

WHAT OUR PARTNERS ARE SAYING

EMPOWERMENT THROUGH TRAINING

At EARO, we don't just provide access to advanced technologies – we also equip our clients' staff with the necessary training for them to get the most out of their research and so enable innovation in Singapore.

Imaging Flowcytometry & Histopathology

"Our team had a wonderful experience using the Akoya-PhenoImager HT system for digital histopathology at EARO. The whole on-boarding and training process was very well-organised. The staff members were friendly and attended to our queries swiftly. All in all, it has been of great value."

JOE POH SHENG YEONG
Principal Scientist
Institute of Molecular and Cell Biology
IMCB

Nov 2021 - Present

High Content Screening & Library Management

"For the past few years, we have engaged EARO-HTP for multiple small molecule screening campaigns. We have worked closely with them to optimise the entire workflow - from assay miniaturisation to establishing imaging and analysis pipelines. It has been a great pleasure working with them and we look forward to our future engagements."

SHAN QUAH
Senior Scientist
A*STAR Skin Research Labs
A*SRL

Apr 2022 - Present

High Content Imaging

"My team is very satisfied with the scientific services from EARO team. They have always responded to all our queries, and their on-site support for setting up our High Content Imaging instruments and training my team members was highly efficient. Access to these instruments, at this stage of our startup, has been of absolute help."

SENIOR SCIENTIST
Local Biotech Startup

Sep 2022 - Present

WHAT OUR PARTNERS ARE SAYING

ENABLING THROUGH INFRASTRUCTURE SUPPORT

EARO provides access to technologies and facilities to allow companies or research groups that are just starting up to kick start their research, even while they are still setting up in-house infrastructure. This allows these fledgling groups to save time and extend their resources to advance their projects further.

Access to Multiple Platforms

"While in the process of building up our own infrastructure and facilities, EARO was able to provide us access to critical equipment that allowed us to jump-start our research and save valuable time. The entire process was, timely, smooth, and professional."

ZOU BIN
Founder & CEO
Axcynsis Therapeutics

Nov 2022 – Present

Access to Multiple Platforms

"Being a member of EARO enabled our team to access state-of-the-art equipment at EDDC, which greatly facilitated our experimental workflow, for example, high-throughput testing, and validation of RNA-targeted small molecules or antisense oligonucleotides predicted by the Genetic Leap computational platform. Working with the staff at EARO/EDDC is a joy, as they are knowledgeable and generous in sharing their experience, welcoming and flexible in exploring solutions tailored to our workflow."

ANDY NG
Head of Research
GeneticLeap

Dec 2021 - Present

Access to EARO Compound Libraries

"The team at EARO understood our needs and was accommodating of our tight timelines.

The entire process was efficient, seamless and the after sales service was particularly on point. This enabled us to quickly validate the various virus screening platforms available in A*IDL. We will definitely engage EARO again for the development of new screening assays for the different pathogens at A*IDL."

ADELINE CHUA
Senior Scientist
Infectious Diseases Labs
ID LABS

Feb 2023

PERCEIVED COMPETENCE

HOW OUR CLIENTS RATED US

Our post-service feedback survey revealed that our clients are satisfied with the quality and effectiveness of services provided by EARO. We strive to be the best service provider for drug discovery in Singapore.

100% rated us **EXCELLENT** for **DOMAIN EXPERTISE**

>95% rated us **EXCELLENT** at **ADDRESSING ENQUIRIES PROMPTLY**

>90% **RESEARCH GROUPS** have engaged our services **MORE THAN ONCE**

>80% ranked us **EXCELLENT** among **SIMILAR SERVICE PROVIDERS**

100% would **RECOMMEND EARO** to others



BEHIND THE SUPPORT

EARO PLATFORMS AND TEAMS



HIGH THROUGHPUT PHENOMICS



EARO OPERATIONS

HIGH THROUGHPUT SCREENING



PROTEIN STRUCTURE & BIOPHYSICS

HIGH THROUGHPUT SCREENING (HTS)

UNIQUE IN SOUTHEAST ASIA

EDDC's High Throughput Screening (HTS) platform has a unique drug screening set of equipment in South-East Asia. It operates an advanced storage system with close to half a million structurally diverse compounds and a complete automation setup for large scale drug screening projects.

The goal of HTS is simple yet powerful: measure the effect of thousands of compounds on various biological systems through a range of biochemical, biophysical and cell-based assays to rapidly identify chemical hits.

Perform a Multitude of Off-the-Shelf Assays

Biochemical, Biophysical, or Cell-based Screening Assays
Up to 16,000 compounds/day
Up to 50 microplates/day

Cherry-picking Compounds
Up to 100 compound plates/day



Compound Libraries

- Curated collection of **>400,000 compounds**
- Regularly **reviewed & revised by in-house chemistry team**
- Up-to-date with the **latest trends in drug discovery**
- Stratified into **diversity & focused sets** to fit specific project needs

HIGH THROUGHPUT SCREENING



JACKIE ANG
PLATFORM HEAD
Wine Scholar

JUSTINA FULWOOD
RESEARCH MANAGER
Fitness Enthusiast

RIAZUL RAZIQ
RESEARCH MANAGER
Games, Movies, AI News

DORIS TEE
SENIOR RESEARCH ASSOCIATE
Hiking, Movies

WONG MEI YEE
RESEARCH ASSOCIATE
Pond Prawning, Crocheting

CHERYL TAN
RESEARCH ASSOCIATE
Baking Delicious Desserts

HIGH THROUGHPUT PHENOMICS (HTP)

A PICTURE IS WORTH A MILLION NUMBERS

By combining automated imaging and quantitative data analysis methods with high-content screening (HCS), the HTP platform is enabling large-scale applications that can be used in drug discovery and systems biology.

High Content Screening

- A high-throughput imaging method to screen compounds in complex cellular systems
- Tailored analysis algorithm designs and assay parameters specific for disease biology
- Customized assays for specific cellular function






Assays for Cellular Function & Disease Biology

- Cell Painting – an unbiased, phenotypic approach for drug discovery and development
- Neurite outgrowth
- Marker expression
- Cellular migration
- Heterogenous co-culture modeling
- 3D Spheroid characterization
- and more...

HIGH THROUGHPUT PHENOMICS



GIRIDHARAN PERIYASAMY
PLATFORM HEAD
Spiritualist

MATAN THANGAVELU
RESEARCH MANAGER
Marathoner

SHIVAJI RIKKA
RESEARCH MANAGER
Biohacker

HONG YUN CHANG
RESEARCH MANAGER
City Adventurer



LINNA LYU
POST DOCTORAL FELLOW
Swimmer, Runner, Hiker

YI LIN GIAN
RESEARCH ASSOCIATE
Explorer of New Cities

CONNIE CHONG
RESEARCH ASSOCIATE
Food & Travel Enthusiast

PROTEIN STRUCTURE & BIOPHYSICS (PSB)

VISUALIZING MACROMOLECULES IN ACTION

Understanding protein-ligand interactions is pivotal for accelerating compound optimization through structure guided design. Our team of experts at the Protein Structure & Biophysics (PSB) platform support the determination of high-resolution structures of proteins and protein-ligand complexes.

Access to both in-house diffractometers and commercial beamline at synchrotrons allows the team to consistently deliver fast turnaround on projects.



Tools of Our Experts

Construct Design & Cloning for optimal protein expression
Protein Expression & Scale Up in *E.coli* expression systems
Protein Purification for high-throughput crystallization
Crystallization Condition Screening to increase chances of success
Biophysics Assays to determine target-ligand engagement
Epitope Mapping to determine binding sites on target antigen proteins
Fragment Based Drug Discovery for finding high quality hits against challenging target proteins and to find novel allosteric/cryptic pockets

PROTEIN STRUCTURE & BIOPHYSICS

NITHYA BABURAJENDRAN

PLATFORM HEAD

Runner, Hiker, Traveler

JOTHI ANANTHARAJAN

SENIOR RESEARCH FELLOW

Food & Travel Enthusiast



YEE KHOON YEO

RESEARCH MANAGER

Fitness Enthusiast

EARO BUSINESS OPERATIONS

The Business Operations team is essential to the success of EARO. They play an integral role in making sure that all processes are running smoothly, that partners are engaged and have their needs met, and that services are provided with quality and within a legal framework.

To further ensure the initiative's success, they survey the local ecosystem regularly to gain a better understanding of what Singapore based companies need. This helps them strategize for future implementations of new technologies so that EARO can continue to be successful.

In 2021, EARO partnered with A*STAR Research Support Centre (RSC) to leverage its well-established network to the local research community and utilise their marketing and administrative support services to assist with EARO's commercial operations.

Thanks to this partnership, EARO can outsource important standard business tasks like signing service contracts and invoicing customers. This has allowed EARO to remain lean and focused on developing and providing the best drug discovery scientific solutions to meet its clients' needs and deliver smooth service experience.

Key Roles

- Project Management
- Liaise Legal Agreements
- Client Engagement
- Costing Strategy
- Commercial Activities
- Quality Management System

EARO BUSINESS TEAM



CHRISTOPHE BODENREIDER
EXECUTIVE DIRECTOR
Outrigger Canoeist

SRAVANTHY MANESH
BUSINESS OPERATIONS MANAGER
Family Vacationer

KAY LIN GOH
BD & ALLIANCE MANAGER
Animal & Nature Enthusiast

SHIVAJI RIKKA
MARKETING MANAGER
X-country Rider

AMELIA YAP
COMPLIANCE MANAGER
Jetsetter


LOOKING AHEAD

STRENGTHENING OUR SERVICE OFFERING

EXPAND SUPPORT FOR DRUG DEVELOPMENT

EARO's core offering has been centred around the early phases of drug discovery. In the coming months and years, we aim to bridge the gap towards pre-clinical drug development by expanding our service offerings to the following areas:

COMPOUND LIBRARIES

The HTS and HTP teams will continue to enrich our compound libraries to optimize the chances of success of our screening campaigns.

PREDICTING TOXICITY

The teams at EARO and EDDC are working on developing novel assays to predict toxicity with morphometric and genomic read-outs. Theses assays will also inform on the mechanism of toxicity.

ANTIBODY DEVELOPMENT

EARO will offer services to characterize antibody functionality and developability. This will address the needs of the increasing number of start-up companies developing large molecules.

MEDICINAL CHEMISTRY

On an ad-hoc basis, EARO will provide support to design small molecules during hit-to-lead and for lead optimization.

IN VIVO PK

EARO will continue to offer support for in vivo assessment of compound stability and metabolism.

EARO

Experimental Drug Development Centre
Academic Research Organisation

www.earo.sg

earo@eddc.sg